Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Rating of “Hold” by Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.11.

Several research analysts recently issued reports on the stock. Bank of America cut their target price on shares of Sutro Biopharma from $1.00 to $0.80 and set an “underperform” rating for the company in a research report on Monday, May 19th. Piper Sandler set a $2.00 price objective on Sutro Biopharma in a report on Friday, March 14th. Wedbush lowered Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $8.00 to $2.00 in a research report on Friday, March 14th. HC Wainwright restated a “neutral” rating and issued a $2.00 target price on shares of Sutro Biopharma in a research report on Tuesday, April 29th. Finally, Citizens Jmp lowered Sutro Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, March 14th.

Institutional Investors Weigh In On Sutro Biopharma

Several institutional investors have recently bought and sold shares of the stock. Vontobel Holding Ltd. increased its stake in Sutro Biopharma by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock worth $46,000 after purchasing an additional 10,000 shares during the period. Rhumbline Advisers increased its stake in shares of Sutro Biopharma by 6.1% in the fourth quarter. Rhumbline Advisers now owns 126,698 shares of the company’s stock worth $233,000 after buying an additional 7,320 shares during the period. Thrivent Financial for Lutherans bought a new stake in Sutro Biopharma during the 4th quarter valued at $178,000. American Century Companies Inc. boosted its position in Sutro Biopharma by 29.1% during the 4th quarter. American Century Companies Inc. now owns 93,033 shares of the company’s stock valued at $171,000 after buying an additional 20,958 shares during the period. Finally, Sei Investments Co. bought a new stake in Sutro Biopharma in the 4th quarter worth $104,000. 96.99% of the stock is currently owned by hedge funds and other institutional investors.

Sutro Biopharma Trading Down 1.5%

Shares of NASDAQ STRO opened at $0.80 on Monday. The business has a 50-day moving average of $0.84 and a 200-day moving average of $1.39. The firm has a market capitalization of $67.49 million, a price-to-earnings ratio of -0.50 and a beta of 1.70. Sutro Biopharma has a 12 month low of $0.52 and a 12 month high of $5.17.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.28). The company had revenue of $17.40 million during the quarter, compared to analysts’ expectations of $11.61 million. Sutro Biopharma had a negative return on equity of 101.89% and a negative net margin of 77.01%. On average, analysts predict that Sutro Biopharma will post -2.92 earnings per share for the current year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.